SCHEMBL7792988

SCHEMBL7792988

COc1ccc(CCNCCNc2nc(C)nc3c2c2ccccc2n3-c2c(C)cc(C)cc2C)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
TP53 P04637 2/20 0.48
LMNA P02545 2/20 0.48
HTT P42858 2/20 0.48
TSHR P16473 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
RXFP1 Q9HBX9 3/20 0.47
CRHR1 P34998 2/20 0.44
KMT2A Q03164 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
APP P05067 7/20 0.44
BCHE P06276 3/20 0.43
ACHE P22303 3/20 0.43
OXTR P30559 1/20 0.42
AVPR1A P37288 1/20 0.42
SMPD1 P17405 1/20 0.42
TTR P02766 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7783154 0.88 CRHR1 (0.50) MAPTTP53LMNAHTTSMN1; SMN2
SCHEMBL7791789 0.85 MAPT (0.42) MAPTTP53LMNAHTTTSHR
SCHEMBL6103775 0.83 CRHR1 (0.56) MAPTTP53LMNAHTTTSHR
SCHEMBL7791863 0.82 TP53 (0.42) MAPTTP53LMNAHTTTSHR
SCHEMBL7791107 0.81 SMPD1 (0.44) MAPTTP53LMNAHTTSMN1; SMN2
SCHEMBL7783144 0.81 SIGMAR1 (0.40) MAPTTP53LMNAHTTRXFP1
SCHEMBL7783150 0.81 RECQL (0.38) MAPTTP53LMNAHTTMAPK1
SCHEMBL7788921 0.78 CRHR1 (0.49) CRHR1KDM4E
SCHEMBL7788894 0.78 CRHR1 (0.62) CRHR1KDM4E
SCHEMBL7788159 0.77 NPY1R (0.52) MAPTTP53LMNASMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NEUROGEN CORPORATION 2001-10-18 US claimed
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NEUROGEN CORPORATION 2001-10-18 US disclosed
US-6221875-B1 TREATING FEEDING DISORDERS, OBESITY, BULIMIA NERVOSA OR HYPERTENSION IN A MAMMAL NEUROGEN CORPORATION 2001-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031758-A1 Substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives: selective neuropeptide Y receptor ligands NPY1R, NPY2R, NPY5R MAPT 3767/4885TP53 4450/4885LMNA 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.